Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: A cohort study

Arthritis Research and Therapy

Volumn 10, Issue 1, 2008, Pages

  Ursum, Jennie ^a   Nielen, Markus M J ^a   van Schaardenburg, Dirkjan ^a,b   van der Horst, Ann R ^c   van de Stadt, Rob J ^a   Dijkmans, Ben A C ^b   Hamann, Dörte ^c  

^a JAN VAN BREEMEN INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Sanquin Diagnostiek   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; C REACTIVE PROTEIN; MUTATED CITRULLINATED VIMENTIN ANTIBODY; UNCLASSIFIED DRUG; CITRULLINE; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; VIMENTIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ARTHRITIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TIME SERIES ANALYSIS; BLOOD; COHORT ANALYSIS; FEMALE; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MUTATION; PATHOPHYSIOLOGY; RADIOGRAPHY; SINGLE BLIND PROCEDURE;

ADULT; ANTIBODIES; ARTHRITIS; CITRULLINE; COHORT STUDIES; FEMALE; HUMANS; MALE; MUTATION; PEPTIDES, CYCLIC; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; VIMENTIN;

EID: 39549108663     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2362     Document Type: Article

References (21)

1. van Schaardenburg D Lagaay AM Otten HG Breedveld FC: The relation between class-specific serum rheumatoid factors and age in the general population. Br J Rheumatol 1993, 32:546-549. 10.1093/rheumatology/ 32.7.546 8339123
2. Masson-Bessiere C Sebbag M Girbal-Neuhauser E Nogueira L Vincent C Senshu T Serre G: The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001, 166:4177-4184. 11238669
3. Pratesi F Tommasi C Anzilotti C Chimenti D Migliorini P: Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2006, 54:733-741. 10.1002/art.21629 16508937
4. Kinloch A Tatzer V Wait R Peston D Lundberg K Donatien P Moyes D Taylor PC Venables PJ: Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005, 7:R1421-R1429. 1297593 16277695 10.1186/ar1845
5. Vossenaar ER Despres N Lapointe E van der HA Lora M Senshu T van Venrooij WJ Menard HA: Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004, 6:R142-R150. 400433 15059278 10.1186/ar1149
6. Riedemann JP Munoz S Kavanaugh A: The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis: A systematic review. Clin Exp Rheumatol 2005, 23:S69-S76. 16273788
7. Ronnelid J Wick MC Lampa J Lindblad S Nordmark B Klareskog L van Vollenhoven RF: Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: Anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005, 64:1744-1749. 10.1136/ ard.2004.033571 15843452
8. Goldbach-Mansky R Lee J McCoy A Hoxworth J Yarboro C Smolen JS Steiner G Rosen A Zhang C Ménard HA Zhou ZJ Palosuo T Van Venrooij WJ Wilder RL Klippel JH Schumacher HR Jr El-Gabalawy HS: Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000, 2:236-243. 17811 11056669 10.1186/ar93
9. Bang H Egerer K Gauliard A Luthke K Rudolph PE Fredenhagen G Berg W Feist E Burmester GR: Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007, 56:2503-2511. 10.1002/art.22817 17665451
10. Dejaco C Klotz W Larcher H Duftner C Schirmer M Herold M: Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R119-1779400. 16859519 10.1186/ar2008
11. Prevoo ML van't Hof MA Kuper HH van Leeuwen MA van de Putte LB van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107 7818570
12. Fries JF Spitz P Kraines RG Holman HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145. 10.1002/art.1780230202 7362664
13. van der Heijde DM van Leeuwen MA van Riel PLCM Koster AM van't Hof MA van Rijswijk MH van de Putte LBA: Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992, 35:26-32. 10.1002/ art.1780350105 1731813
14. Twisk JW: Longitudinal data analysis. A comparison between generalized estimating equations and random coefficient analysis. Eur J Epidemiol 2004, 19:769-776. 10.1023/B:EJEP.0000036572.00663.f2 15469034
15. Bruynesteyn K van der Heijde D Boers M Saudan A Peloso P Paulus H Houben H Griffiths B Edmonds J Bresnihan B Boonen A van der Linden S: Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/ Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002, 46:913-920. 10.1002/art.10190 11953967
16. van Gestel AM Prevoo ML van't Hof MA Rijswijk MH van de Putte LB van Riel PL; Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39:34-40. 10.1002/art.1780390105 8546736
17. Aotsuka S Okawa-Takatsuji M Nagatani K Nagashio C Kano T Nakajima K Ito K Mimori A: A retrospective study of the fluctuation in serum levels of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:475-481. 16095115
18. Greiner A Plischke H Kellner H Gruber R: Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci 2005, 1050:295-303. 10.1196/ annals.1313.031 16014545
19. Bizzaro N Tonutti E Tozzoli R Villalta D; Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 2007, 53:1527-1533. 10.1373/clinchem.2007.087569 17586589
20. Coenen D Verschueren P Westhovens R Bossuyt X: Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/ peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007, 53:498-504. 10.1373/clinchem.2006.078063 17259232
21. Berglin E Johansson T Sundin U Jidell E Wadell G Hallmans G Rantapaa-Dahlqvist S: Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006, 65:453-458. 10.1136/ard.2005.041376 16176994